NEW YORK CITY -- In the last year, we've been forced to look at close-ups of our faces on video call screens, been introduced to new skin issues such as 'Mask-ne' all without the option to get a ...

SAN FRANCISCO — Among patients with symptomatic, severe native aortic regurgitation at high surgical risk, the JenaValve Trilogy transcatheter heart valve system (JenaValve Technology) met its primary ...

Philips Respironics initiated a voluntary recall to address a potentially defective component on the Trilogy Ventilator power management board, which could affect the function of the device. If this ...

WASHINGTON, DC—Further follow-up from the ALIGN-AR trial confirm the safety and continued efficacy of the Trilogy heart valve system (JenaValve) for the treatment of patients with severe, symptomatic ...

Transcatheter aortic valve implantation to treat aortic regurgitation (AR) appears to be a relatively safe and effective option in high-risk patients ineligible for surgery, according to a small ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...

IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced results from an ...

MURRYSVILLE, Pa., Feb. 19, 2014 /PRNewswire/ -- Respironics, Inc., a Philips Healthcare business, today announced a worldwide recall of approximately 600 Philips Respironics Trilogy Ventilators, ...